176 related articles for article (PubMed ID: 33518033)
1. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products.
Sirrs SM; Arthus MF; Bichet DG; Rockman-Greenberg C; LeMoine K; Morel CF; Lachmann R; Lynd LD; Wasim S; West ML; Hollak C
Value Health; 2021 Feb; 24(2):268-273. PubMed ID: 33518033
[TBL] [Abstract][Full Text] [Related]
2. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Blankart CR; Stargardt T; Schreyögg J
Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
[TBL] [Abstract][Full Text] [Related]
3. Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.
McGettigan P; Alonso Olmo C; Plueschke K; Castillon M; Nogueras Zondag D; Bahri P; Kurz X; Mol PGM
Drug Saf; 2019 Nov; 42(11):1343-1351. PubMed ID: 31302896
[TBL] [Abstract][Full Text] [Related]
4. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
5. Cost of Operating Central Cancer Registries and Factors That Affect Cost: Findings From an Economic Evaluation of Centers for Disease Control and Prevention National Program of Cancer Registries.
Tangka FK; Subramanian S; Beebe MC; Weir HK; Trebino D; Babcock F; Ewing J
J Public Health Manag Pract; 2016; 22(5):452-60. PubMed ID: 26642226
[TBL] [Abstract][Full Text] [Related]
6. An Analysis of Cancer Registry Cost Data: Methodology and Results.
Beebe MC; Subramanian S; Tangka FK; Weir HK; Babcock F; Trebino D
J Registry Manag; 2018; 45(2):58-64. PubMed ID: 31533128
[TBL] [Abstract][Full Text] [Related]
7. Orphan therapies: making best use of postmarket data.
Maro JC; Brown JS; Dal Pan GJ; Li L
J Gen Intern Med; 2014 Aug; 29 Suppl 3(Suppl 3):S745-51. PubMed ID: 25029972
[TBL] [Abstract][Full Text] [Related]
8. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
9. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
10. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study.
Crisafulli S; Sultana J; Ingrasciotta Y; Addis A; Cananzi P; Cavagna L; Conter V; D'Angelo G; Ferrajolo C; Mantovani L; Pastorello M; Scondotto S; Trifirò G
Expert Opin Drug Saf; 2019 Jun; 18(6):497-509. PubMed ID: 31059293
[TBL] [Abstract][Full Text] [Related]
11. Imposed registries within the European postmarketing surveillance system: Extended analysis and lessons learned for regulators.
Pacurariu A; Plueschke K; Olmo CA; Kurz X
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):823-826. PubMed ID: 29749086
[TBL] [Abstract][Full Text] [Related]
12. Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS).
Clarke JT; Giugliani R; Sunder-Plassmann G; Elliott PM; Pintos-Morell G; Hernberg-Ståhl E; Malmenäs M; Beck M;
Value Health; 2011; 14(6):862-6. PubMed ID: 21914507
[TBL] [Abstract][Full Text] [Related]
13. Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective.
Feltelius N; Gedeborg R; Holm L; Zethelius B
Ups J Med Sci; 2017 Jun; 122(2):136-147. PubMed ID: 28276780
[TBL] [Abstract][Full Text] [Related]
14. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
Maier WC; Christensen RA; Anderson P
Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
[TBL] [Abstract][Full Text] [Related]
15. RSA and registries: the quest for phased introduction of new implants.
Nelissen RG; Pijls BG; Kärrholm J; Malchau H; Nieuwenhuijse MJ; Valstar ER
J Bone Joint Surg Am; 2011 Dec; 93 Suppl 3():62-5. PubMed ID: 22262426
[TBL] [Abstract][Full Text] [Related]
16. Economic assessment of central cancer registry operations, Part III: Results from 5 programs.
Tangka F; Subramanian S; Beebe MC; Trebino D; Michaud F
J Registry Manag; 2010; 37(4):152-5. PubMed ID: 21688745
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
18. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
19. Developing and testing a cost data collection instrument for noncommunicable disease registry planning.
Subramanian S; Tangka F; Edwards P; Hoover S; Cole-Beebe M
Cancer Epidemiol; 2016 Dec; 45 Suppl 1(Suppl 1):S4-S12. PubMed ID: 27726980
[TBL] [Abstract][Full Text] [Related]
20. A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.
Czech M; Baran-Kooiker A; Atikeler K; Demirtshyan M; Gaitova K; Holownia-Voloskova M; Turcu-Stiolica A; Kooiker C; Piniazhko O; Konstandyan N; Zalis'ka O; Sykut-Cegielska J
Front Public Health; 2019; 7():416. PubMed ID: 32117845
[No Abstract] [Full Text] [Related]
[Next] [New Search]
